AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ZIV, TAP, KHC and VNDA

March 28, 2019

CEDARHURST, N.Y., March 28, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

VelocityShares Daily Inverse VIX Medium Term Exchange Traded Notes (NASDAQGM: ZIV)Investors Affected: June 30, 2017 - February 5, 2018

A class action has commenced on behalf of certain shareholders in VelocityShares Daily Inverse VIX Medium Term Exchange Traded Notes. The filed complaint alleges that throughout the class period defendants made materially false or misleading statements relating to the risks of investing in ZIV including that: (i) the inverse ETNs was not appropriate for managing daily trading risks; (ii) Credit Suisse had designed the ZIV to fail under certain market conditions; (iii) Credit Suisse had offered and sold more inverse ETNs than the market could bear, which would enable Credit Suisse to cause the collapse of the inverse ETNs when the opportunity presented itself; and (iv) Credit Suisse could actively manipulate inverse ETNs by precipitating an acute liquidity event in volatility markets including markets for VIX futures.

Shareholders may find more information at https://kseclaw.com/securities/velocityshares-daily-inverse-vix-medium-term-exchange-traded-notes-loss-submission-form/?wire=3

Molson Coors Brewing Company (NYSE: TAP)Investors Affected: February 14, 2017 - February 12, 2019

A class action has commenced on behalf of certain shareholders in Molson Coors Brewing Company. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Molson Coors failed to properly reconcile the outside basis deferred income tax liability for Molson Coors’ investment in its MillerCoors, LLC partnership; (2) consequently, Molson Coors misreported net income in its consolidated financial statements for the fiscal years ending December 31, 2016 and December 31, 2017, resulting in an overall downward revision to net income; (3) Molson Coors lacked adequate internal controls over financial reporting; and (4) as a result, defendants’ statements about Molson Coors’ business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/molson-coors-brewing-company-loss-submission-form/?wire=3

The Kraft Heinz Company (NASDAQ: KHC)Investors Affected: July 6, 2015 - February 21, 2019

A class action has commenced on behalf of certain shareholders in The Kraft Heinz Company. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants misrepresented that the Zero Based Budgeting (“ZBB”) and other cost-saving measures would deliver increased profitability while simultaneously maintaining base business momentum; (ii) Defendants failed to disclose known trends that were negatively impacting the Company’s organic sales growth and profitability; (iii) Defendants falsely represented the ability of the Company’s pipeline of new products to generate organic growth; (iv) Defendants falsely stated that “main-stays like Oscar Mayer [and] Kraft cheese” were “tangible drivers of [a] turnaround in the second half of 2018”; (v) Defendants failed to disclose known trends that resulted in the intangible asset impairments associated with the Company’s Oscar Mayer and Kraft brands; and (vi) Defendants failed to disclose known trends that resulted in the goodwill impairments affecting its U.S. Refrigerated and Canada Retail divisions.

Shareholders may find more information at https://kclasslaw.com/securities/the-kraft-heinz-company-loss-submission-form/?wire=3

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)Investors Affected: November 4, 2015 - February 11, 2019

A class action has commenced on behalf of certain shareholders in Vanda Pharmaceuticals Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Vanda was engaged in a fraudulent scheme in which it promoted the off-label use of Fanapt and Hetlioz; (2) Vanda was fraudulently receiving drug reimbursements from the government by abusing Medicare, Medicaid, and Tricare programs; (3) as a result of the scheme, Vanda faced legal action from the government; (4) Vanda’s promotional materials for Fanapt and Hetlioz were false and misleading, garnering regulatory scrutiny from the U.S. Food and Drug Administration; and (5) as a result, defendants’ statements about Vanda’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/vanda-pharmaceuticals-inc-loss-submission-form/?wire=3

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock.

CONTACT:Kuznicki Law PLLCDaniel Kuznicki, Esq.445 Central Avenue, Suite 344Cedarhurst, NY 11516Email: dk@kclasslaw.com Phone: (347) 696-1134Cell: (347) 690-0692Fax: (347) 348-0967